AbbVie makes a hefty play to boost aesthetics business, paying $550M for non-invasive body sculpting device
When AbbVie chose to prop up its Allergan Aesthetics unit as a separate business post-merger, it set off some alarm bells that a spinoff or sale could be in the offing. But now, AbbVie is making an opportunistic play to boost the aesthetics business, adding a long-delayed body sculpting product into the fold.
AbbVie’s Allergan Aesthetics unit will pay $550 million in cash to scoop up drugmaker Soliton and Resonic, its sound-wave device to improve the appearance of cellulite, the company’s said Monday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.